News
Abstract 2876: BR116: An antibody drug conjugate targeting CDH17 for gastrointestinal cancer therapy
Notably, our unique conjugation platform CysX™ offers site-specific, stable and irreversible conjugation. CysX™ not only prevents payload detachment during circulation and reducing the off-target ...
BRY812 is a monomethyl auristatin E (MMAE)-conjugated humanized IgG1 ADC against LIV-1. With Bioray’s irreversible conjugation method CysLink TM, BRY812 enables superior in vivo stability and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback